Second-generation antipsychotics in the treatment of major depressive disorder: Current evidence

Expert Review of Neurotherapeutics

Volumn 13, Issue 7, 2013, Pages 851-870

  Han, Changsu ^a   Wang, Sheng Min ^b   Kato, Masaki ^c   Lee, Soo Jung ^b   Patkar, Ashwin A ^d   Masand, Prakash S ^e   Pae, Chi Un ^b,d  

^a Korea University College of Medicine   (South Korea)

^b The Catholic University of Korea College of Medicine   (South Korea)

^c KANSAI MEDICAL UNIVERSITY   (Japan)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e Global Medical Education Inc   (United States)

Author keywords

Antidepressant; Augmentation; Clinical trial; Major depressive disorder; Second generation antipsychotic

Indexed keywords

AMINEPTINE; AMISULPRIDE; AMITRIPTYLINE; ARIPIPRAZOLE; ASENAPINE; BUSPIRONE; CITALOPRAM; DULOXETINE; FLUOXETINE; ILOPERIDONE; IMIPRAMINE; LURASIDONE; NEUROLEPTIC AGENT; NORTRIPTYLINE; OLANZAPINE; PALIPERIDONE; PAROXETINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; SERTRALINE; TRAZODONE; VALPROIC ACID; VENLAFAXINE; VILOXAZINE; ZIPRASIDONE;

AKATHISIA; ANTIDEPRESSANT ACTIVITY; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); COGNITIVE THERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL (TOPIC); DIZZINESS; DOPAMINERGIC TRANSMISSION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; EXCITOTOXICITY; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GALACTORRHEA; HAMILTON SCALE; HEADACHE; HUMAN; INCREASED APPETITE; INSOMNIA; LOW DRUG DOSE; MAJOR DEPRESSION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PERIPHERAL EDEMA; PREFRONTAL CORTEX; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SEDATION; SEROTONINERGIC SYSTEM; SHEEHAN DISABILITY SCALE; SIDE EFFECT; SOCIAL INTERACTION; SOCIAL STATUS; SOMNOLENCE; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; TREATMENT DURATION; TREATMENT RESISTANT DEPRESSION; TREATMENT RESPONSE; WEIGHT GAIN; XEROSTOMIA;

ANTIPSYCHOTIC AGENTS; DEPRESSIVE DISORDER, MAJOR; HUMANS; TREATMENT OUTCOME;

EID: 84883143577     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.2013.811901     Document Type: Review

References (137)

1. Kessler RC, Berglund P, Demler O et al.; National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289(23), 3095-3105 (2003).
2. Rush AJ, Warden D, Wisniewski SR et al. STAR*D: revising conventional wisdom. CNS Drugs 23(8), 627-647 (2009).
3. Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur. Neuropsychopharmacol. 19(1), 34-40 (2009).
4. Nierenberg AA, Husain MM, Trivedi MH et al. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol. Med. 40(1), 41-50 (2010).
5. Paykel ES, Ramana R, Cooper Z, Hayhurst H, Kerr J, Barocka A. Residual symptoms after partial remission: an important outcome in depression. Psychol. Med. 25(6), 1171-1180 (1995).
6. Thase ME. Evaluating antidepressant therapies: remission as the optimal outcome. J. Clin. Psychiatry 64(Suppl. 13), 18-25 (2003).
7. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am. J. Psychiatry 157(Suppl. 4), 1-45 (2000).
8. Bauer M, Whybrow PC, Angst J, Versiani M, Möller HJ; World Federation of Societies Biological Psychiatry Task Force on Treatment Guidelines for Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: acute and continuation treatment of major depressive disorder. World J. Biol. Psychiatry 3(1), 5-43 (2002).
9. Anderson IM, Ferrier IN, Baldwin RC et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J. Psychopharmacol. (Oxford) 22(4), 343-396 (2008).
10. Kennedy SH, Lam RW, Cohen NL, Ravindran AV; CANMAT Depression Work Group. Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. Can. J. Psychiatry 46(Suppl. 1), S38-S58 (2001).
11. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am. J. Psychiatry 166(9), 980-991 (2009).
12. Robertson MM, Trimble MR. Neuroleptics as antidepressants. Neuropharmacology 20(12B), 1335-1336 (1981).
13. Sagud M, Mihaljevic-Peleš A, Begic D et al. Antipsychotics as antidepressants: what is the mechanism? Psychiatr. Danub. 23(3), 302-307 (2011).
14. Yoshino T, Nisijima K, Katoh S, Yui K, Nakamura M. Tandospirone potentiates the fluoxetine-induced increases in extracellular dopamine via 5-HT(1A) receptors in the rat medial frontal cortex. Neurochem. Int. 40(4), 355-360 (2002).
15. Gobert A, Rivet JM, Cistarelli JM, Millan MJ. Buspirone enhances duloxetine- and fluoxetine-induced increases in dialysate levels of dopamine and noradrenaline, but not serotonin, in the frontal cortex of freely moving rats. J. Neurochem. 68(3), 1326-1329 (1997).
16. DeLeon A, Patel NC, Crismon ML. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin. Ther. 26(5), 649-666 (2004).
17. Pae CU, Serretti A, Patkar AA, Masand PS. Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence. CNS Drugs 22(5), 367-388 (2008).
18. Burris KD, Molski TF, Xu C et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J. Pharmacol. Exp. Ther. 302(1), 381-389 (2002).
19. De Vry J, Schreiber R, Melon C, Dalmus M, Jentzsch KR. 5-HT1A receptors are differentially involved in the anxiolytic- and antidepressant-like effects of 8-OH-DPAT and fluoxetine in the rat. Eur. Neuropsychopharmacol. 14(6), 487-495 (2004).
20. Dremencov E, Newman ME, Kinor N et al. Hyperfunctionality of serotonin-2C receptor-mediated inhibition of accumbal dopamine release in an animal model of depression is reversed by antidepressant treatment. Neuropharmacology 48(1), 34-42 (2005).
21. Pira L, Mongeau R, Pani L. The atypical antipsychotic quetiapine increases both noradrenaline and dopamine release in the rat prefrontal cortex. Eur. J. Pharmacol. 504(1-2), 61-64 (2004).
22. Tatsumi M, Jansen K, Blakely RD, Richelson E. Pharmacological profile of neuroleptics at human monoamine transporters. Eur. J. Pharmacol. 368(2-3), 277-283 (1999).
23. Schmidt AW, Lebel LA, Howard HR Jr, Zorn SH. Ziprasidone: a novel anti-psychotic agent with a unique human receptor binding profile. Eur. J. Pharmacol. 425(3), 197-201 (2001).
24. Wesolowska A. Potential role of the 5-HT6 receptor in depression and anxiety: an overview of preclinical data. Pharmacol. Rep. 62(4), 564-577 (2010).
25. Hedlund PB. The 5-HT7 receptor and disorders of the nervous system: an overview. Psychopharmacology (Berl.) 206(3), 345-354 (2009).
26. Tascedda F, Lovati E, Blom JM et al. Regulation of ionotropic glutamate receptors in the rat brain in response to the atypical antipsychotic seroquel (quetiapine fumarate). Neuropsychopharmacology 21(2), 211-217 (1999).
27. de Borja Gonçalves Guerra A, Castel S, Benedito-Silva AA, Calil HM. Neuroendocrine effects of quetiapine in healthy volunteers. Int. J. Neuropsychopharmacol. 8(1), 49-57 (2005).
28. Myint AM, Kim YK, Verkerk R, Scharpé S, Steinbusch H, Leonard B. Kynurenine pathway in major depression: evidence of impaired neuroprotection. J. Affect. Disord. 98(1-2), 143-151 (2007).
29. McEwen BS, Olié JP. Neurobiology of mood, anxiety, and emotions as revealed by studies of a unique antidepressant: tianeptine. Mol. Psychiatry 10(6), 525-537 (2005).
30. Cosi C, Waget A, Rollet K, Tesori V, Newman-Tancredi A. Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation. Brain Res. 1043(1-2), 32-41 (2005).
31. Blier P, Szabo ST. Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. J. Clin. Psychiatry 66(Suppl. 8), 30-40 (2005).
32. Adson DE, Kushner MG, Fahnhorst TA. Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin reuptake inhibitors. J. Affect. Disord. 86(1), 99-104 (2005).
33. Papakostas GI, Petersen TJ, Kinrys G et al. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatmentresistant major depressive disorder. J. Clin. Psychiatry 66(10), 1326-1330 (2005).
34. Pae CU, Patkar AA, Jun TY, Lee C, Masand PS, Paik IH. Aripiprazole augmentation for treatment of patients with inadequate antidepressants response. Depress. Anxiety 24(7), 522-526 (2007).
35. Simon JS, Nemeroff CB. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder. J. Clin. Psychiatry 66(10), 1216-1220 (2005).
36. Patkar AA, Peindl K, Mago R, Mannelli P, Masand PS. An open-label, rater-blinded, augmentation study of aripiprazole in treatment-resistant depression. Prim. Care Companion J. Clin. Psychiatry 8(2), 82-87 (2006).
37. Rutherford B, Sneed J, Miyazaki M et al. An open trial of aripiprazole augmentation for SSRI non-remitters with late-life depression. Int. J. Geriatr. Psychiatry 22(10), 986-991 (2007).
38. Barbee JG, Conrad EJ, Jamhour NJ. Aripiprazole augmentation in treatmentresistant depression. Ann. Clin. Psychiatry 16(4), 189-194 (2004).
39. Worthington JJ 3rd, Kinrys G, Wygant LE, Pollack MH. Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int. Clin. Psychopharmacol. 20(1), 9-11 (2005).
40. Schüle C, Baghai TC, Eser D et al. Mirtazapine monotherapy versus combination therapy with mirtazapine and aripiprazole in depressed patients without psychotic features: a 4-week open-label parallel-group study. World J. Biol. Psychiatry 8(2), 112-122 (2007).
41. Hellerstein DJ, Batchelder S, Hyler S et al. Aripiprazole as an adjunctive treatment for refractory unipolar depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 32(3), 744-750 (2008).
42. Berman RM, Marcus RN, Swanink R et al. The efficacy and safety of aripiprazole as Han, Wang, Kato et al. www.expert-reviews.com 867 Review adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry 68(6), 843-853 (2007).
43. Marcus RN, McQuade RD, Carson WH et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J. Clin. Psychopharmacol. 28(2), 156-165 (2008).
44. Berman RM, Fava M, Thase ME et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr. 14(4), 197-206 (2009).
45. Fava M, Mischoulon D, Iosifescu D et al. A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). Psychother. Psychosom. 81(2), 87-97 (2012).
46. Mischoulon D, Witte J, Levy M et al. Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebocontrolled, efficacy trial. J. Clin. Psychiatry 73(3), 353-357 (2012).
47. Thase ME, Trivedi MH, Nelson JC et al. Examining the efficacy of adjunctive aripiprazole in major depressive disorder: a pooled analysis of 2 studies. Prim. Care Companion J. Clin. Psychiatry 10(6), 440-447 (2008).
48. Trivedi MH, Corey-Lisle PK, Guo Z, Lennox RD, Pikalov A, Kim E. Remission, response without remission, and non-response in major depressive disorder: impact on functioning. Int. Clin. Psychopharmacol. 24(3), 133-138 (2009).
49. Nelson JC, Thase ME, Bellocchio EE et al. Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy. Int. Clin. Psychopharmacol. 27(3), 125-133 (2012).
50. Steffens DC, Nelson JC, Eudicone JM et al. Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: a pooled subpopulation analysis. Int. J. Geriatr. Psychiatry 26(6), 564-572 (2011).
51. Trivedi MH, Thase ME, Fava M et al. Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features. J. Clin. Psychiatry 69(12), 1928-1936 (2008).
52. Nelson JC, Mankoski R, Baker RA et al. Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression: a post-hoc, pooled analysis of two large, placebocontrolled studies. J. Affect. Disord. 120(1-3), 133-140 (2010).
53. Reimherr FW, Martin ML, Eudicone JM et al. A pooled MADRS/IDS cross-correlation analysis: clinician and patient self-report assessment of improvement in core depressive symptoms with adjunctive aripiprazole. J. Clin. Psychopharmacol. 30(3), 300-305 (2010).
54. Berman RM, Thase ME, Trivedi MH et al. Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder. Neuropsychiatr. Dis. Treat. 7, 303-312 (2011).
55. Fava M, Wisniewski SR, Thase ME et al. Metabolic assessment of aripiprazole as adjunctive therapy in major depressive disorder: a pooled analysis of 2 studies. J. Clin. Psychopharmacol. 29(4), 362-367 (2009).
56. Fava M, Dording CM, Baker RA et al. Effects of adjunctive aripiprazole on sexual functioning in patients with major depressive disorder and an inadequate response to standard antidepressant monotherapy: a post hoc analysis of 3 randomized, double-blind, placebo- controlled studies. Prim. Care Companion CNS Disord. 13(1), pii: PCC.10m00994(2011).
57. Nelson JC, Thase ME, Trivedi MH et al. Safety and tolerability of adjunctive aripiprazole in major depressive disorder: a pooled post hoc analysis (studies CN138-139 and CN138-163). Prim. Care Companion J. Clin. Psychiatry 11(6), 344-352 (2009).
58. Anderson IM, Sarsfield A, Haddad PM. Efficacy, safety and tolerability of quetiapine augmentation in treatment resistant depression: an open-label, pilot study. J. Affect Disord. 117(1-2), 116-119 (2009).
59. Soares CN, Frey BN, Haber E, Steiner M. A pilot, 8-week, placebo lead-in trial of quetiapine extended release for depression in midlife women: impact on mood and menopause-related symptoms. J. Clin. Psychopharmacol. 30(5), 612-615 (2010).
60. Katila H, Mezhebovsky I, Mulroy A et al. Randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder. Am. J. Geriatr. Psychiatry (2012) (Epub ahead of print).
61. Bortnick B, El-Khalili N, Banov M et al. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study. J. Affect. Disord. 128(1-2), 83-94 (2011).
62. Liebowitz M, Lam RW, Lepola U, Datto C, Sweitzer D, Eriksson H. Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial. Depress. Anxiety 27(10), 964-976 (2010).
63. Weisler R, Joyce M, McGill L, Lazarus A, Szamosi J, Eriksson H; Moonstone Study Group. Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study. CNS Spectr. 14(6), 299-313 (2009).
64. Cutler AJ, Montgomery SA, Feifel D, Lazarus A, Aström M, Brecher M. Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study. J. Clin. Psychiatry 70(4), 526-539 (2009).
65. Earley WMA, Wang G. Double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder (MDD). Presented at: The 8th International Forum on Mood and Anxiety Disorder. Vienna, Austria, 12-14 November 2008.
66. El-Khalili N, Joyce M, Atkinson S et al. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int. J. Neuropsychopharmacol. 13(7), 917-932 (2010).
67. Bauer M, Pretorius HW, Constant EL, Earley WR, Szamosi J, Brecher M. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J. Clin. Psychiatry 70(4), 540-549 (2009).
68. Garakani A, Martinez JM, Marcus S et al. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder. Int. Clin. Psychopharmacol. 23(5), 269-275 (2008).
69. Chaput Y, Magnan A, Gendron A. The co-administration of quetiapine or placebo to cognitive-behavior therapy in treatment refractory depression: a preliminary trial. BMC Psychiatry 8, 73 (2008).
70. McIntyre A, Gendron A, McIntyre A. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. Depress. Anxiety 24(7), 487-494 (2007).
71. Wijkstra J, Burger H, van den Broek WW et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatr. Scand. 121(3), 190-200 (2010).
72. Maneeton N, Maneeton B, Srisurapanont M, Martin SD. Quetiapine monotherapy in acute phase for major depressive disorder: a meta-analysis of randomized, placebo-controlled trials. BMC Psychiatry 12, 160 (2012).
73. Thase ME, Demyttenaere K, Earley WR, Gustafsson U, Udd M, Eriksson H. Extended release quetiapine fumarate in major depressive disorder: analysis in patients with anxious depression. Depress. Anxiety 29(7), 574-586 (2012).
74. Weisler RH, Montgomery SA, Earley WR, Szamosi J, Lazarus A. Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, doubleblind, placebo-controlled studies. Int. Clin. Psychopharmacol. 27(1), 27-39 (2012).
75. Shelton RC, Tollefson GD, Tohen M et al. A novel augmentation strategy for treating resistant major depression. Am. J. Psychiatry 158(1), 131-134 (2001).
76. Shelton RC, Williamson DJ, Corya SA et al. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J. Clin. Psychiatry 66(10), 1289-1297 (2005).
77. Corya SA, Williamson D, Sanger TM, Briggs SD, Case M, Tollefson G. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress. Anxiety 23(6), 364-372 (2006).
78. Thase ME, Corya SA, Osuntokun O et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatmentresistant major depressive disorder. J. Clin. Psychiatry 68(2), 224-236 (2007).
79. Rothschild AJ, Williamson DJ, Tohen MF et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. J. Clin. Psychopharmacol. 24(4), 365-373 (2004).
80. Meyers BS, Flint AJ, Rothschild AJ et al.; STOP-PD Group. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Arch. Gen. Psychiatry 66(8), 838-847 (2009).
81. Trivedi MH, Thase ME, Osuntokun O et al. An integrated analysis of olanzapine/ fluoxetine combination in clinical trials of treatment-resistant depression. J. Clin. Psychiatry 70(3), 387-396 (2009).
82. Tohen M, Case M, Trivedi MH, Thase ME, Burke SJ, Durell TM. Olanzapine/ fluoxetine combination in patients with treatment-resistant depression: rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies. J. Clin. Psychiatry 71(4), 451-462 (2010).
83. Corya SA, Andersen SW, Detke HC et al. Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study. J. Clin. Psychiatry 64(11), 1349-1356 (2003).
84. Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J. Clin. Psychiatry 60(4), 256-259 (1999).
85. Viner MW, Chen Y, Bakshi I, Kamper P. Low-dose risperidone augmentation of antidepressants in nonpsychotic depressive disorders with suicidal ideation. J. Clin. Psychopharmacol. 23(1), 104-106 (2003).
86. Mahmoud RA, Pandina GJ, Turkoz I et al. Risperidone for treatment-refractory major depressive disorder: a randomized trial. Ann. Intern. Med. 147(9), 593-602 (2007).
87. Reeves H, Batra S, May RS, Zhang R, Dahl DC, Li X. Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. J. Clin. Psychiatry 69(8), 1228-1336 (2008).
88. Keitner GI, Garlow SJ, Ryan CE et al. A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. J. Psychiatr. Res. 43(3), 205-214 (2009).
89. Rapaport MH, Gharabawi GM, Canuso CM et al. Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology 31(11), 2505-2513 (2006).
90. Alexopoulos GS, Canuso CM, Gharabawi GM et al. Placebo-controlled study of relapse prevention with risperidone augmentation in older patients with resistant depression. Am. J. Geriatr. Psychiatry 16(1), 21-30 (2008).
91. Fang Y, Yuan C, Xu Y et al.; OPERATION Study Team. A pilot study of the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult Chinese patients with treatment-resistant major depression. J. Clin. Psychopharmacol. 31(5), 638-642 (2011).
92. Papakostas GI, Vitolo OV, Ishak WW et al. A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial of ziprasidone as monotherapy for major depressive disorder. J. Clin. Psychiatry 73(12), 1541-1547 (2012).
93. Papakostas GI, Petersen TJ, Nierenberg AA et al. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J. Clin. Psychiatry 65(2), 217-221 (2004).
94. Dunner DL, Amsterdam JD, Shelton RC, Loebel A, Romano SJ. Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study. J. Clin. Psychiatry 68(7), 1071-1077 (2007).
95. Rocca P, Marchiaro L, Rasetti R, Rivoira E, Bogetto F. A comparison of paroxetine versus paroxetine plus amisulpride in the treatment of dysthymic disorder: efficacy and psychosocial outcomes. Psychiatry Res. 112(2), 145-152 (2002).
96. Rocca P, Fonzo V, Ravizza L et al. A comparison of paroxetine and amisulpride in the treatment of dysthymic disorder. J. Affect. Disord. 70(3), 313-317 (2002).
97. Zanardi R, Smeraldi E. A double-blind, randomised, controlled clinical trial of acetyl-l-carnitine vs. amisulpride in the treatment of dysthymia. Eur. Neuropsychopharmacol. 16(4), 281-287 (2006).
98. Cassano GB, Jori MC; AMIMAJOR Group. Efficacy and safety of amisulpride 50 mg versus paroxetine 20 mg in major depression: a randomized, double-blind, parallel group study. Int. Clin. Psychopharmacol. 17(1), 27-32 (2002).
99. Ravizza L. Amisulpride in medium-term treatment of dysthymia: a six-month, double-blind safety study versus amitriptyline. AMILONG investigators. J. Psychopharmacol. (Oxford) 13(3), 248-254 (1999).
100. Boyer P, Lecrubier Y, Stalla-Bourdillon A, Fleurot O. Amisulpride versus amineptine and placebo for the treatment of dysthymia. Neuropsychobiology 39(1), 25-32 (1999).
101. Smeraldi E. Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission: a doubleblind, comparative study. J. Affect. Disord. 48(1), 47-56 (1998).
102. Lecrubier Y, Boyer P, Turjanski S, Rein W. Amisulpride versus imipramine and placebo in dysthymia and major depression. Amisulpride Study Group. J. Affect. Disord. 43(2), 95-103 (1997).
103. León CA, Vigoya J, Conde S, Campo G, Castrillón E, León A. [Comparison of the effect of amisulpride and viloxazine in the treatment of dysthymia]. Acta Psiquiatr. Psicol. Am. Lat. 40(1), 41-49 (1994).
104. Amore M, Jori MC; AMISERT Investigators. Faster response on amisulpride 50 mg versus sertraline 50-100 mg in patients with dysthymia or double depression: a randomized, double-blind, parallel group study. Int. Clin. Psychopharmacol. 16(6), 317-324 (2001).
105. Yang FW, Liang CS. Paliperidone augmentation for treatment-resistant depression: a case report. J. Clin. Psychopharmacol. 31(2), 245-246 (2011).
106. Tarazi FI, Stahl SM. Iloperidone, asenapine and lurasidone: a primer on their current status. Expert Opin. Pharmacother. 13(13), 1911-1922 (2012).
107. Mischoulon D, Nierenberg AA, Kizilbash L, Rosenbaum JF, Fava M. Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: a survey of clinicians. Can. J. Psychiatry 45(5), 476-481 (2000).
108. Gaynes BN, Dusetzina SB, Ellis AR et al. Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D. J. Clin. Psychopharmacol. 32(1), 114-119 (2012).
109. Wisniewski SR, Fava M, Trivedi MH et al. Acceptability of second-step treatments to depressed outpatients: a STAR*D report. Am. J. Psychiatry 164(5), 753-760 (2007).
110. Warden D, Rush AJ, Wisniewski SR et al. What predicts attrition in second step medication treatments for depression?: a STAR*D Report. Int. J. Neuropsychopharmacol. 12(4), 459-473 (2009).
111. Papakostas GI, Petersen TJ, Green C et al. A description of next-step switching versus augmentation practices for outpatients with treatment-resistant major depressive disorder enrolled in an academic specialty clinic. Ann. Clin. Psychiatry 17(3), 161-165 (2005).
112. Rush AJ, Trivedi MH, Stewart JW et al. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am. J. Psychiatry 168(7), 689-701 (2011).
113. Pae CU, Han C, Jun TY. Do we need more than one antidepressant for patients with major depressive disorder? Expert Rev. Neurother. 11(11), 1561-1564 (2011).
114. Rush AJ, Trivedi MH, Wisniewski SR et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry 163(11), 1905-1917 (2006).
115. Berlim MT, Turecki G. Definition, assessment, and staging of treatment-resistant refractory major depression: a review ofcurrent concepts and methods. Can. J. Psychiatry 52(1), 46-54 (2007).
116. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr. Clin. North Am. 19(2), 179-200 (1996).
117. Lin CH, Lin SH, Jang FL. Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study. J. Clin. Psychopharmacol. 31(5), 563-568 (2011).
118. Rush AJ, Wisniewski SR, Zisook S et al. Is prior course of illness relevant to acute or longer-term outcomes in depressed out-patients? A STAR*D report. Psychol. Med. 42(6), 1131-1149 (2012).
119. Nierenberg AA, Trivedi MH, Gaynes BN et al. Effectiveness study of venlafaxine-XR combined with aripiprazole for chronic or recurrent major depressive disorder. Aus. New Zealand J. Psychiatry 43(10), 956-967 (2009).
120. Chen SJ, Hsiao YL, Shen TW, Chen ST. The effectiveness and safety of adjunctive aripiprazole in Taiwanese patients with antidepressant-refractory major depressive disorder: a prospective, open-label trial. J. Clin. Psychopharmacol. 32(1), 56-60 (2012).
121. Jang SH, Park YN, Jae YM et al. The symptom frequency characteristics of the Hamilton Depression Rating Scale and possible symptom clusters of depressive disorders in Korea: the CRESCEND Study. Psychiatry Investig. 8(4), 312-319 (2011).
122. Hwang SH, Rhee MK, Kang RH et al. Development and validation of a screening scale for depression in Korea: the Lee and Rhee Depression Scale. Psychiatry Investig. 9(1), 36-44 (2012).
123. Park YM, Lee SH, Park EJ. Usefulness of LDAEP to predict tolerability to SSRIs in major depressive disorder: a case report. Psychiatry Investig. 9(1), 80-82 (2012).
124. Lee MS, Ahn YM, Chung S, Walton R, Raskin J, Kim MS. The effect of initial duloxetine dosing strategy on nausea in Korean patients with major depressive disorder. Psychiatry Investig. 9(4), 391-399 (2012).
125. Son SH, Jo H, Rim HD et al. A comparative study on alexithymia in depressive, somatoform, anxiety, and psychotic disorders among Koreans. Psychiatry Investig. 9(4), 325-331 (2012).
126. Pae CU, Forbes A, Patkar AA. Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data. CNS Drugs 25(2), 109-127 (2011).
127. Gao K, Kemp DE, Ganocy SJ, Gajwani P, Xia G, Calabrese JR. Antipsychoticinduced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J. Clin. Psychopharmacol. 28(2), 203-209 (2008).
128. McElroy SL, Guerdjikova A, Mori N, Keck PE Jr. Therapeutic potential of new second generation antipsychotics for major depressive disorder. Expert Opin. Investig. Drugs 19(12), 1527-1544 (2010).
129. McIntyre RS, Park KY, Law CW et al. The association between conventional antidepressants and the metabolic syndrome: a review of the evidence and clinical implications. CNS Drugs 24(9), 741-753 (2010).
130. Chen J, Gao K, Kemp DE. Second-generation antipsychotics in major depressive disorder: update and clinical perspective. Curr. Opin. Psychiatry 24(1), 10-17 (2011).
131. Lam RW, Kennedy SH, Grigoriadis S et al.; Canadian Network for Mood and Anxiety Treatments (CANMAT). Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J. Affect. Disord. 117(Suppl. 1), S26-S43 (2009).
132. Härter M, Klesse C, Bermejo I, Schneider F, Berger M. Unipolar depression: diagnostic and therapeutic recommendations from the current S3/National Clinical Practice Guideline. Dtsch. Arztebl. Int. 107(40), 700-708 (2010).
133. Pae CU, Sohi MS, Seo HJ et al. Quetiapine XR: current status for the treatment of major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 34(7), 1165-1173 (2010).
134. Nelson JC, Pikalov A, Berman RM. Augmentation treatment in major depressive disorder: focus on aripiprazole. Neuropsychiatr. Dis. Treat. 4(5), 937-948 (2008).
135. Möller HJ. Antipsychotic and antidepressive effects of second generation antipsychotics: two different pharmacological mechanisms? Eur. Arch. Psychiatry Clin. Neurosci. 255(3), 190-201 (2005).
136. Wang SM, Han C, Lee SJ, Patkar AA, Pae CU, Fleischhacker WW. Paliperidone: a review of clinical trial data and clinical implications. Clin. Drug Investig. 32(8), 497-512 (2012).
137. Yatham LN. Mood stabilization and the role of antipsychotics. Int. Clin. Psychopharmacol. 17(Suppl. 3), S21-S27 (2002).